Clovis Oncology Inc (CLVS) is Upgraded by Credit Suisse to Outperform

Clovis Oncology Inc (CLVS) was Upgraded by Credit Suisse to ” Outperform”. Earlier the firm had a rating of “Neutral ” on the company shares. Credit Suisse advised their investors in a research report released on Sep 21, 2016.

Many Wall Street Analysts have commented on Clovis Oncology Inc. Company shares were Reiterated by Mizuho on Aug 24, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $15 .Clovis Oncology Inc was Initiated by SunTrust to “Buy” on Aug 5, 2016.

On the company’s financial health, Clovis Oncology Inc reported $-2.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-2.11.During the same quarter in the previous year, the company posted $-2.10 EPS.

Clovis Oncology Inc opened for trading at $31.44 and hit $35.75 on the upside on Tuesday, eventually ending the session at $34.83, with a gain of 12.68% or 3.92 points. The heightened volatility saw the trading volume jump to 78,47,227 shares. Company has a market cap of $1,341 M.

In a different news, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at $104.18 per share price. According to the SEC, on Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at $97.80 per share price. On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at $91.91 per share price, according to the Form-4 filing with the securities and exchange commission.

Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Clovis Oncology Inc

Leave a Reply

Clovis Oncology Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Clovis Oncology Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.